Trial Profile
A phase II trial of CC-122 in patients with non-Hodgkin's lymphoma
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Feb 2018
Price :
$35
*
At a glance
- Drugs Avadomide (Primary)
- Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Celgene Corporation
- 25 Jan 2018 According to Celgene Corporation media release, this trial is expected to initiate in 2018.
- 27 Jul 2017 According to Celgene Corporation media release, this trial is expected to initiate in second half of 2017.
- 14 Jan 2016 New trial record